Antimicrobial De-escalation Strategy in Medical Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01066013 |
Recruitment Status : Unknown
Verified January 2010 by Fraser Health.
Recruitment status was: Active, not recruiting
First Posted : February 10, 2010
Last Update Posted : August 18, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infections | Other: Antimicrobial de-escalation strategy | Not Applicable |
This is an open-label, case-control, pilot study involving medical patients with serious infections who are prescribed meropenem or piperacillin/tazobactam, at Surrey Memorial Hospital. Patients in the experimental arm (cases) will be required to provide an informed consent. A team consisting of an infectious diseases specialist, medical microbiologist and clinical pharmacists will prospectively assess antimicrobial therapy in the enrolled subjects in the prospective arm and make recommendations for antimicrobial de-escalation.
The control group will consist of subjects drawn from historic data of patients on the same medical unit(s) who will be matched based on age, sex, use of broadspectrum antibiotics (meropenem or piperacillin/tazobactam) and infectious diseases diagnosis.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Antimicrobial De-escalation Strategy in Medical Patients |
Study Start Date : | February 2010 |
Estimated Primary Completion Date : | May 2010 |
Estimated Study Completion Date : | June 2010 |
Arm | Intervention/treatment |
---|---|
Experimental: Prospective Antimicrobial de-escalation arm
Antimicrobial de escalation team will assess therapy and make recommendations to (a) change to antibiotic(s) with narrow spectrum,(b) stop antibiotics, (c) order new cultures/investigations or (d) consult with specialists or ID service for full evaluation (if patient's condition is worsening).
|
Other: Antimicrobial de-escalation strategy
The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice. |
No Intervention: Restrospective control arm
The control subjects will be drawn from historic data of patients on the same medical unit(s) and will be matched based on age, antibiotics, sex, and infectious diseases diagnosis.
|
- Number of patients who had therapy with meropenem or piperacillin/tazobactam de-escalated by the de-escalation team. [ Time Frame: 7 days ]
- Clinical efficacy (clinical improvement or complete resolution of infection) [ Time Frame: 7 days ]
- Appropriateness of broadspectrum antibiotic (meropenem or piperacillin/tazobactam) prior to de-escalation [ Time Frame: 7 days ]
- Cost and consumption (usage data) of antibiotics [ Time Frame: 7 days ]
- All cause mortality [ Time Frame: 14 days ]
- Length of stay in the hospital [ Time Frame: 14 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 19 years and over
- Suspected or confirmed infection for which a Meropenem and/or Piperacillin/Tazobactam is prescribed. This will include any patient who is other concomitant antibiotic(s) such as Vancomycin
- Subject admitted to SMH medical unit(s)
- Pregnant patient (or patients wishing to become pregnant)
Exclusion Criteria:
- Age less than 19 years
- Granulocytopenia (< 1x109/L)
- Allergy or intolerance to meropenem or piperacillin-tazobactam.
- Febrile Neutropenia
- Cystic Fibrosis
Responsible Party: | Anisha Lakhani, Fraser Health Authority |
ClinicalTrials.gov Identifier: | NCT01066013 |
Other Study ID Numbers: |
FHREB 2009-093 |
First Posted: | February 10, 2010 Key Record Dates |
Last Update Posted: | August 18, 2010 |
Last Verified: | January 2010 |
Antimicrobial De escalation Meropenem Piperacillin tazobactam Medical patients |
Appropriate use Cost savings Antimicrobial De-escalation strategy |
Anti-Infective Agents Anti-Bacterial Agents |